142 related articles for article (PubMed ID: 32583656)
1. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma.
Allard L; Albarel F; Bertherat J; Caron PJ; Cortet C; Courtillot C; Delemer B; Jublanc C; Maiter D; Nunes ML; Raverot G; Sarfati J; Salenave S; Corruble E; Choucha W; Chanson P
Eur J Endocrinol; 2020 Aug; 183(2):221-231. PubMed ID: 32583656
[TBL] [Abstract][Full Text] [Related]
2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonists and antipsychotics.
Molitch ME
Eur J Endocrinol; 2020 Sep; 183(3):C11-C13. PubMed ID: 32508315
[TBL] [Abstract][Full Text] [Related]
4. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists.
Chanson P
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101711. PubMed ID: 36280567
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
6. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma.
Acquati S; Pizzocaro A; Tomei G; Giovanelli M; Libè R; Faglia G; Ambrosi B
J Neurosurg Sci; 2001 Jun; 45(2):65-9. PubMed ID: 11533529
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
9. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
10. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
11. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
15. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
16. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
17. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
18. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
19. Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder.
Melkersson K; Hulting AL
Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):6-10. PubMed ID: 10738858
[TBL] [Abstract][Full Text] [Related]
20. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients.
Salenave S; Ancelle D; Bahougne T; Raverot G; Kamenický P; Bouligand J; Guiochon-Mantel A; Linglart A; Souchon PF; Nicolino M; Young J; Borson-Chazot F; Delemer B; Chanson P
J Clin Endocrinol Metab; 2015 Mar; 100(3):1177-86. PubMed ID: 25532043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
